United States ex rel. Lacorte v. Roche Biomedical Laboratories, Inc.

182 F.R.D. 480, 1998 U.S. Dist. LEXIS 16980, 1998 WL 743708
CourtDistrict Court, M.D. North Carolina
DecidedAugust 21, 1998
DocketNos. 2:96CV00417, 2:96CV01024
StatusPublished

This text of 182 F.R.D. 480 (United States ex rel. Lacorte v. Roche Biomedical Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. North Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States ex rel. Lacorte v. Roche Biomedical Laboratories, Inc., 182 F.R.D. 480, 1998 U.S. Dist. LEXIS 16980, 1998 WL 743708 (M.D.N.C. 1998).

Opinion

MEMORANDUM OPINION

TILLEY, District Judge.

This case is before the Court on a Motion to Intervene [Doc. # 40 in 2:96CV00417] filed by Ms. Ramona Wagner and Ms. Jeanine Dehner (the “Relators”).1 The United States, on the other hand, has filed a Motion for Entry of Order of Dismissal [Doc. # 69 in 2:96CV00417; Doe. #37 in 2.-96CV01024]. ’For the reasons stated below, the Relators’ Motion to Intervene is GRANTED and the United States’ Motion is DENIED.

[482]*482I.

The history of this matter is as follows: the Relators are both former billing clerks for Allied Clinical Laboratories, Inc. (“Allied”) in Cincinnati, Ohio. On February 7, 1994, in the United States District Court for the Southern District of Ohio, the Relators filed a qui tam action alleging violations of the False Claims Act (“FCA”), 31 U.S.C. § 3729 et seq., and several state law violations. The United States intervened in the Ohio case in July of 1994, and the case was then settled and dismissed with prejudice on March 20, 1995. On that date, the United States, the Relators, and Allied jointly executed a Settlement Agreement and Release (“Settlement I”) concerning the alleged violations of the FCA. (See Mot. Intervene Ex. 1. ) Settlement I noted that the United States and Allied had entered a separate Corporate Integrity Agreement (“CIA”), in which Allied was required to submit periodic reports concerning its potential wrongdoing to the United States. (See id. 11J; id. Ex. 2. ) Also on that date, the Relators and Allied executed a separate Confidential Settlement Agreement and Mutual Release (“Settlement II”). (See Def.’s Mem. Resp. Mot. Intervene Ex. B (under seal).)

Since the dismissal of the Ohio case, Allied and at least two other medical laboratories, Roche Biomedical Laboratories (“Roche”) and National Health Laboratories (“NHL”), have merged with Laboratory Corporation of America (“LabCorp”), which is headquartered in Burlington, North Carolina. All of these laboratories have faced charges that they violated the FCA.

On November 21, 1996, the United States, LabCorp, Roche, NHL, Allied, two relators who filed qui tam actions against Roche, and two relators who filed qui tam actions against NHL, all executed a Settlement Agreement and Release (“Global Settlement”) concerning claims asserted by the United States against Roche, NHL, and Allied. (See App. United States’ Post>-Hr’g Mem.) Some portion of the claims settled in the Global Settlement may have grown out of disclosures made pursuant to the Ohio CIA. (See id. Ex. 20, H1ÍV-Z.)

The Relators filed their Motion to Intervene approximately two weeks after the Global Settlement was made public. At a hearing held on February 19, 1998, the Rela-tors made clear that their claim in this case pertains only to that portion of the Global Settlement, if any, which arose from disclosures made pursuant to the CIA. (See Tr. 2/19/98 Hr’g at 6-7, 37-38.)

II.

There are two considerations in determining whether the Relators should be allowed into this case. The first is whether the FCA bars them from intervening. If it does not, the second consideration is whether the Federal Rules of Civil Procedure either require or allow intervention in this case. The Rela-tors’ Motion should be granted because the FCA allows and the Rules of Civil Procedure require that the Relators be allowed to intervene.

A. Applicability of the False Claim Act’s Bar on Intervention

In construing a statute, a court should first determine whether “the language at issue has a plain and unambiguous meaning with regard to the particular dispute in the ease.” Robinson v. Shell Oil Co., 519 U.S. 337, 117 S.Ct. 843, 846, 136 L.Ed.2d 808 (1997). If the language is unambiguous and the overall statutory scheme is coherent and consistent, the inquiry ends. See id. If the language is ambiguous, a court should look to the broader context and purpose of the statute to help ascertain the particular language’s meaning. See id., 519 U.S. 337, 117 S.Ct. at 848.

The FCA as it applies to this case cannot be properly interpreted without reference to its overall purpose. The statute contains only one provision which directly addresses intervention:

When a person brings an action under this subsection, no person other than the Government may intervene or bring a related action based on the facts underlying the pending action.

31 U.S.C. § 3730(b)(5). On its own, this provision might be read to unambiguously [483]*483prevent a grant of the Relator’s Motion in this case. “[W]ith regard to the particular dispute in th[is] ease,” Robinson, 519 U.S. 337, 117 S.Ct. at 846, however, another section of the FCA is inconsistent with such a reading of § 3730(b)(5). The portion of the FCA which describes the rights of relators whose qui tam actions have been taken over by the Government reads in relevant part:

Notwithstanding subsection (b), the Government may elect to pursue its claim through any alternate remedy available to the Government, including any administrative proceeding to determine a civil money penalty. If any such alternate remedy is pursued in another proceeding, the person initiating the action shall have the same rights in such proceeding as such person would have had if the action had continued under this section.

Id. § 3730(c)(5). Subsection (c)(5) appears to grant relators an unconditional right to participate in “any alternate remedy” pursued by the Government. “Any alternate remedy” should be given as broad a construction as the phrase would naturally receive. The phrase is not ambiguous, nor does its typically broad construction conflict with the FCA’s overall scheme.

The particular facts of this case illustrate the conflict between these two subsections. If, as the Relators argue, some portion of the Global Settlement is attributable to the information on which they based the Ohio ease or information arising from the Ohio case and they are otherwise entitled to some fraction of the relevant portion, subsection (c)(5) would seem to allow them to intervene, while subsection (b)(5) would seem to prevent their intervention. See United States ex rel. Burr v. Blue Cross and Blue Shield of Florida, Inc., 153 F.R.D. 172, 174 (M.D.Fla.1994) (recognizing potential of subsection (c)(5) to create exception to subsection (b)(5)). This inconsistency makes the meaning of the statute ambiguous and therefore requires an examination of the statute’s overall purpose and scheme.

The subsections at issue became a part of the FCA when it was amended by the False Claims Amendment Act, Pub.L. No. 99-562, 100 Stat. 3153 (1986). The legislative history of these particular subsections suggests that Congress did not consider situations like the one presented by this case when drafting either of these provisions.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
182 F.R.D. 480, 1998 U.S. Dist. LEXIS 16980, 1998 WL 743708, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-ex-rel-lacorte-v-roche-biomedical-laboratories-inc-ncmd-1998.